These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

433 related articles for article (PubMed ID: 28765689)

  • 1. Present and future of metastatic colorectal cancer treatment: A review of new candidate targets.
    Martini G; Troiani T; Cardone C; Vitiello P; Sforza V; Ciardiello D; Napolitano S; Della Corte CM; Morgillo F; Raucci A; Cuomo A; Selvaggi F; Ciardiello F; Martinelli E
    World J Gastroenterol; 2017 Jul; 23(26):4675-4688. PubMed ID: 28765689
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence of RAS mutations and individual variation patterns among patients with metastatic colorectal cancer: A pooled analysis of randomised controlled trials.
    Peeters M; Kafatos G; Taylor A; Gastanaga VM; Oliner KS; Hechmati G; Terwey JH; van Krieken JH
    Eur J Cancer; 2015 Sep; 51(13):1704-13. PubMed ID: 26049686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-epidermal growth factor receptor monoclonal antibodies in metastatic colorectal cancer: a meta-analysis.
    Song QB; Wang Q; Hu WG
    World J Gastroenterol; 2015 Apr; 21(14):4365-72. PubMed ID: 25892888
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictive and prognostic factors in the complex treatment of patients with colorectal cancer.
    László L
    Magy Onkol; 2010 Dec; 54(4):383-94. PubMed ID: 21163770
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epidermal growth factor receptor ligands: targets for optimizing treatment of metastatic colorectal cancer.
    Foroughi S; Tie J; Gibbs P; Burgess AW
    Growth Factors; 2019 Dec; 37(5-6):209-225. PubMed ID: 31878812
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The evolution of biomarkers to guide the treatment of metastatic colorectal cancer.
    Davis LE
    Am J Manag Care; 2018 Apr; 24(7 Suppl):S107-S117. PubMed ID: 30207665
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical use of anti-epidermal growth factor receptor monoclonal antibodies in metastatic colorectal cancer.
    Patel DK
    Pharmacotherapy; 2008 Nov; 28(11 Pt 2):31S-41S. PubMed ID: 18980550
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metastatic colorectal cancer- third line therapy and beyond.
    Foo T; Roy A; Karapetis C; Townsend A; Price T
    Expert Rev Anticancer Ther; 2024 May; 24(5):219-227. PubMed ID: 38526540
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab.
    Yen LC; Uen YH; Wu DC; Lu CY; Yu FJ; Wu IC; Lin SR; Wang JY
    Ann Surg; 2010 Feb; 251(2):254-60. PubMed ID: 20010090
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current and future targets and therapies in metastatic colorectal cancer.
    Dzunic M; Petkovic I; Cvetanovic A; Vrbic S; Pejcic I
    J BUON; 2019; 24(5):1785-1792. PubMed ID: 31786838
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Personalizing medicine for metastatic colorectal cancer: current developments.
    Marques AM; Turner A; de Mello RA
    World J Gastroenterol; 2014 Aug; 20(30):10425-31. PubMed ID: 25132758
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Targeted therapies for metastatic colorectal cancer].
    Kito Y; Yamazaki K
    Nihon Rinsho; 2015 Aug; 73(8):1384-90. PubMed ID: 26281694
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive and prognostic biomarkers for targeted therapy in metastatic colorectal cancer.
    Asghar U; Hawkes E; Cunningham D
    Clin Colorectal Cancer; 2010 Dec; 9(5):274-81. PubMed ID: 21208841
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted therapy for metastatic colorectal cancer.
    Price TJ; Tang M; Gibbs P; Haller DG; Peeters M; Arnold D; Segelov E; Roy A; Tebbutt N; Pavlakis N; Karapetis C; Burge M; Shapiro J
    Expert Rev Anticancer Ther; 2018 Oct; 18(10):991-1006. PubMed ID: 30019590
    [TBL] [Abstract][Full Text] [Related]  

  • 15. KRAS status and resistance to epidermal growth factor receptor tyrosine-kinase inhibitor treatment in patients with metastatic colorectal cancer: a meta-analysis.
    Li W; Shi Q; Wang W; Liu J; Ren J; Li Q; Hou F
    Colorectal Dis; 2014 Nov; 16(11):O370-8. PubMed ID: 25155261
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted Therapy of Colorectal Cancer.
    Seeber A; Gastl G
    Oncol Res Treat; 2016; 39(12):796-802. PubMed ID: 27889786
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive and prognostic markers in the treatment of metastatic colorectal cancer (mCRC): personalized medicine at work.
    Stintzing S; Stremitzer S; Sebio A; Lenz HJ
    Hematol Oncol Clin North Am; 2015 Feb; 29(1):43-60. PubMed ID: 25475572
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted therapy in metastatic colorectal cancer -- an example of personalised medicine in action.
    Heinemann V; Douillard JY; Ducreux M; Peeters M
    Cancer Treat Rev; 2013 Oct; 39(6):592-601. PubMed ID: 23375249
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Cetuximab for patients with metastatic colorectal cancer-from the result of recent clinical trials].
    Ariyama H; Kusaba H; Baba E
    Gan To Kagaku Ryoho; 2010 May; 37(5):782-6. PubMed ID: 20495306
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review.
    Tol J; Punt CJ
    Clin Ther; 2010 Mar; 32(3):437-53. PubMed ID: 20399983
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.